Canaccord raised the firm’s price target on Corcept Therapeutics to $78 from $38 and keeps a Buy rating on the shares. The firm raised its target because it believes based on 2Q results that the company is seeing increased uptake of Korlym usage in the very patient population that the Phase IV CATALYST study was designed to identify and confirm. That is a previously undiagnosed Cushing’s syndrome population living with uncontrolled T2D and/or hypertension even while on poly-pharmacy and elevated levels of cortisol.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics price target raised to $38 from $35 at Piper Sandler
- Corcept Therapeutics price target raised to $45 from $40 at H.C. Wainwright
- Corcept Therapeutics Releases Q2 2024 Financial Results
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics options imply 9.8% move in share price post-earnings